Whitehawk Therapeutics (WHWK) Convertible Debt (2020)

Whitehawk Therapeutics' (WHWK) quarterly Convertible Debt came in at $1.1 million in Q4 2020.

Whitehawk Therapeutics (WHWK) Convertible Debt (2020) Analysis & Trends

Whitehawk Therapeutics (WHWK) has 1 years of Convertible Debt data on file, last reported at $1.1 million in Q4 2020.

On a quarterly basis, Convertible Debt changed N/A year-over-year to $1.1 million in Q4 2020; TTM through Dec 2020 was $1.1 million, a N/A change from a year earlier, with the FY2020 full-year figure at $1.1 million, changed N/A from the prior year.
Convertible Debt for Q4 2020 stood at $1.1 million.
Over the last five years, Convertible Debt for WHWK reached as high as $1.1 million in Q4 2020 and fell as low as $1.1 million in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Whitehawk Therapeutics	256.87 Mn	45.62 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	1.10 Mn